AbCellera Biologics (NASDAQ:ABCL – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare AbCellera Biologics to similar businesses based on the strength of its valuation, dividends, risk, earnings, analyst recommendations, institutional ownership and profitability.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for AbCellera Biologics and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 7 | 2 | 2.91 |
| AbCellera Biologics Competitors | 9923 | 15313 | 45658 | 1602 | 2.54 |
AbCellera Biologics presently has a consensus target price of $16.20, indicating a potential upside of 40.99%. As a group, “Biotechnology” companies have a potential upside of 126.42%. Given AbCellera Biologics’ peers higher possible upside, analysts clearly believe AbCellera Biologics has less favorable growth aspects than its peers.
Earnings and Valuation
This table compares AbCellera Biologics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| AbCellera Biologics | $67.85 million | -$146.41 million | -23.94 |
| AbCellera Biologics Competitors | $738.96 million | $10.45 million | -18.81 |
AbCellera Biologics’ peers have higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares AbCellera Biologics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
| AbCellera Biologics Competitors | -12,224.09% | -202.33% | -31.23% |
Institutional & Insider Ownership
61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
AbCellera Biologics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, AbCellera Biologics’ peers have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Summary
AbCellera Biologics beats its peers on 9 of the 13 factors compared.
AbCellera Biologics Company Profile
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
